ABSTRACT
OBJECTIVES: Fibrodysplasia ossificans progressiva (FOP) is one of the most catastrophic forms of genetic heterotopic ossification (HO). FOP is characterized by severe, progressive inflammatory flare-ups, that often lead to HO. The flare-ups are associated with increased inflammatory cytokine production, suggesting auto-inflammatory features driven by interleukin-1ß (IL-1ß). This study describes the short- and long-term responses of FOP patients to anti-IL-1 therapy. METHODS: Previously, we reported that a patient with FOP treated with anti-IL-1 agents showed dramatically lower rates of flare-ups, improved flare-up symptoms, decreased use of glucocorticoids, and apparently decreased size of residual lesions. Plasma analyses also showed marked elevation in IL-1ß levels during a FOP flare, further supporting a role of IL-1ß in the pathogenesis of FOP flares. Here, we report results from long-term therapy with IL-1 inhibitors in that patient, and describe 3 additional patients, from two medical centers. RESULTS: All 4 patients showed persistent improvement in flare activity during treatment with IL-1 inhibitors, with minimal formation of new HO sites. Two patients who stopped therapy experienced resurgence of flare activity that was re-suppressed upon re-initiation. These patients had IL-1ß levels comparable to those in IL-1ß-driven diseases. Child Health Assessment Questionnaires confirmed extensive subjective improvements in the pain and general health visual analogue scales. CONCLUSION: This case series demonstrates significant benefits from IL-1 inhibitors for reducing flare activity and improving the general health of patients with FOP. These data provide strong support for additional studies to better understand the function of IL-1 inhibition, primarily in reducing formation new HO. FUNDING: RH received support from the International FOP Association ACT grant; ECH received support from NIH/NIAMS R01AR073015 and the UCSF Robert Kroc Chair in Connective Tissue and Rheumatic Diseases III.
ABSTRACT
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare progressive genetic disease effecting one in a million individuals. During their life, patients with FOP progressively develop bone in the soft tissues resulting in increasing immobility and early death. A mutation in the ACVR1 gene was identified as the causative mutation of FOP in 2006. After this, the pathophysiology of FOP has been further elucidated through the efforts of research groups worldwide. In 2015, a workshop was held to gather these groups and discuss the new challenges in FOP research. Here we present an overview and update on these topics.
Subject(s)
Endocrinology/trends , Myositis Ossificans , Congresses as Topic , Endocrinology/methods , Expert Testimony/trends , History, 21st Century , Humans , Mutation/physiology , Myositis Ossificans/diagnosis , Myositis Ossificans/etiology , Myositis Ossificans/pathology , Myositis Ossificans/therapy , Ossification, Heterotopic/genetics , Ossification, Heterotopic/pathologySubject(s)
Arthritis, Juvenile , Quality of Life , Surveys and Questionnaires , Adolescent , Child , Cultural Diversity , Female , Humans , MaleABSTRACT
Se presenta el caso de una paciente de 16 años de edad sin enfermedades previas, a quien se le diagnosticó lupus eritematoso sistémico (LES) con daño renal al mes de detectarse una infección por citomegalovirus (CMV). Tanto la nefritis como la enfermedad sistémica evolucionaron favorablemente con tratamiento combinado de metilprednisona y mofetil micofenolato. No se administraron fármacos antivirales y no hubo reactivación de la virosis durante el tratamiento. El objetivo de esta comunicación es describir a una adolescente, quien desarrolló LES inmediatamente después de una infección por CMV.